Neximmune Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Neximmune Inc (NEXI) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Neximmune Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Neximmune Inc | - | - | - | Yes |
| Competitors combined (59) | ||||
| High-Confidence Competitors (12) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
NEXI Stock Performance relative to its Competitors
NEXI Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Adlai Nortye Ltd | 282.9% | Outperformed |
| 2 | Iovance Biotherapeutics inc | 282.9% | Outperformed |
| 3 | Nurix Therapeutics Inc | 282.9% | Outperformed |
| 4 | Enliven Therapeutics Inc | 282.9% | Outperformed |
| 5 | Whitehawk Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Neximmune Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Neximmune Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Neximmune Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Neximmune Inc | 0.00 | - |
| Novartis Ag | 275,752.75 | 56,674.00 |
| Gilead Sciences Inc | 183,342.50 | 30,457.00 |
| Gsk Plc | 97,120.03 | 43,093.89 |
| Madrigal Pharmaceuticals Inc | 14,564.18 | 1,283.94 |
| Hutchmed china Limited | 12,718.02 | 548.51 |
| SUBTOTAL | 645,951.77 | 134,542.87 |
Sign in to see all competitors of Neximmune Inc .
Sources: Neximmune Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Neximmune Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Neximmune Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| GlaxoSmithKline plc | Named by the company | 85% |
| Fate Therapeutics, Inc. | Named by the company | 85% |
| Mustang Bio, Inc. | Named by the company | 85% |
| Cue Biopharma Inc | Named by the company | 85% |
| Gilead Sciences, Inc. | Named by the company | 85% |
| Novartis AG | Named by the company | 85% |
| Marker Therapeutics inc | Named by the company | 85% |
| ADAPTIN BIO, INC. | Named by the company | 85% |
| Amgen Inc. | Named by the company | 85% |
| Johnson & Johnson | Named by the company | 85% |
| Bristol-Myers Squibb Company | Named by the company | 85% |
| MacroGenics, Inc. | Named by the company | 85% |
| Atara Biotherapeutics Inc | Named by the company | 85% |
| Adaptimmune Therapeutics Plc | Named by the company | 85% |
| Iovance Biotherapeutics inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Neximmune Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Neximmune Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Madrigal Pharmaceuticals Inc | Reportable 100.00 % |
| Hutchmed china Limited | Other Ventures segment 47.94 % |
| Rhythm Pharmaceuticals Inc | Single Reportable 100.00 % |
| Iovance Biotherapeutics inc | Single reportable segment 100.00 % |
| Supernus Pharmaceuticals inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Neximmune Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Neximmune Inc | 0 | - | -515,421 |
| Novartis Ag | 275,753 | 752,973 | 185,566 |
| Gilead Sciences Inc | 183,343 | 1,791,588 | -190,588 |
| Gsk Plc | 97,120 | 169,660,977 | 32,662,867 |
| Madrigal Pharmaceuticals Inc | 14,564 | 1,403,213 | -355,295 |
| Hutchmed china Limited | 12,718 | 703,221 | 586,836 |
| PEERS TOTAL | 645,952 | 1,338,096 | 159,950 |
Neximmune Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Gilead Sciences Inc | United States 70.78 % |
| Hutchmed china Limited | CN 74.28 % |
| Iovance Biotherapeutics inc | US 98.66 % |
| Xoma Royalty Corporation | CH 54.36 % |
| Adc Therapeutics Sa | United States 96.08 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Neximmune Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 498 companies in Neximmune Inc's industry classification, broader than the peer set above. Market cap in millions of $.Neximmune Inc ranks #0 of 498 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 816, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,029,931 | 19.10 % |
| 2 | Johnson and Johnson | 643,198 | 11.93 % |
| 3 | Beone Medicines Ltd | 553,175 | 10.26 % |
| 4 | Abbvie Inc | 461,540 | 8.56 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 0 | Neximmune Inc | 0 | 0.00 % |
Market cap and industry share for the rest of Neximmune Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-30.
Neximmune Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (345 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 24.9x | - |
| EV / EBITDA | - | 17.1x | - |
| P/B | 1.0x | 4.5x | -3.5x |
| Return on Equity | -542.45 % | industry aggregate | -554.77 % |
| Return on Invested Capital | -265.81 % | -2.85 % (avg) | -262.96 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Neximmune Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2021 | 2022 | 2023 |
|---|---|---|---|
| Revenue Growth | - | - | - |
| Operating Margin | - | - | - |
| Return on Invested Capital | -25.90 % | -60.80 % | -125.26 % |
| P/E | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Neximmune Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 816 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Neximmune Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Neximmune Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Neximmune Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 554.8 points below the industry aggregate.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of tracked competitors (45.60 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-40.3% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Neximmune Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Neximmune Inc | 0.92 | 1.20 | - |
| Novartis Ag | 0.42 | 1.12 | 0.02 |
| Gilead Sciences Inc | - | 1.54 | 1.27 |
| Gsk Plc | 0.16 | 0.82 | 0.87 |
| Madrigal Pharmaceuticals Inc | 0.72 | 3.52 | 0.60 |
| Hutchmed china Limited | 0.23 | 4.96 | 0.10 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Neximmune Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Neximmune Inc | Q2 2024 | - | - |
| Novartis Ag | Q4 2025 | +9.6 % | +17.0 % |
| Gilead Sciences Inc | Q2 2026 | +10.2 % | - |
| Gsk Plc | Q4 2025 | +7.5 % | +120.0 % |
| Madrigal Pharmaceuticals Inc | Q2 2026 | +71.2 % | - |
| Hutchmed china Limited | Q4 2025 | -13.0 % | +1,099.2 % |
| PEERS TOTAL | +8.7 % | -26.7 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Neximmune Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Neximmune Inc | Q2 2024 | - | - |
| Novartis Ag | Q4 2025 | +18.3 % | +13.3 % |
| Gilead Sciences Inc | Q2 2026 | +5.2 % | +30.8 % |
| Gsk Plc | Q4 2025 | +7.2 % | -0.6 % |
| Madrigal Pharmaceuticals Inc | Q2 2026 | - | - |
| Hutchmed china Limited | Q4 2025 | -3.6 % | -44.2 % |
Neximmune Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Neximmune Inc | - | - | - |
| Novartis Ag | 12.59% | 12.62% | 30.00% |
| Gilead Sciences Inc | - | - | - |
| Gsk Plc | 10.09% | 44.94% | 38.67% |
| Madrigal Pharmaceuticals Inc | - | - | - |
| Hutchmed china Limited | 26.11% | 30.87% | 36.98% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Neximmune Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Neximmune Inc | - | - |
| Novartis Ag | 19.72 | 4.87 |
| Gilead Sciences Inc | - | 6.02 |
| Gsk Plc | 16.99 | 2.25 |
| Madrigal Pharmaceuticals Inc | - | 11.34 |
| Hutchmed china Limited | 28.02 | 23.19 |
| PEERS AVERAGE | 40.22 | 4.80 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.